Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy)

Burden of rotavirus infections in Liguria, northern Italy: hospitalisations and potential savings by vaccination

“…Our calculation of the number of avoidable cases confirmed that universal vaccination would reduce the impact of RV infection on ED admissions, hospitalisations and admissions to the SO unit; similar finding have been reported by other authors [26] [27]. These results are confirmed by recent data on surveillance in the USA, where the introduction of RV vaccination into the paediatric immunization schedule has reduced the burden of RV gastroenteritis [28].…”

A critical literature review of health economic evaluations of rotavirus vaccination

“…Although most studies suggest that the net costs of vaccination are positive, some concluded that vaccination is cost-saving from a societal perspective (Australia, 56 Belgium, 13 Italy, 29,30 UK, 39,41 and USA 73 ). However, the results of these studies were often contradicted by other results for the same countries.…”

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries

“…In several analyses, both the healthcare payer and societal perspectives were used, [33][34][35][36][37][38][39][40] whereas other studies were conducted from either a societal [41,42] or a healthcare payer perspective. [43] Two studies adopted a 'limited societal' perspective, which excluded indirect costs but included out-ofpocket medical expenses along with other direct medical costs.…”

“…[43] Two studies adopted a 'limited societal' perspective, which excluded indirect costs but included out-ofpocket medical expenses along with other direct medical costs. [44,45] Some studies focused only on RIX4414, [36,37,[42][43][44] while others also included indirect comparisons with the pentavalent rotavirus vaccine [34,35,38,39,41,45] or, in some cases, the universal rotavirus vaccination program being evaluated allowed for the use of either RIX4414 or the pentavalent rotavirus vaccine. [33,40,45] A wide range of results was reported across the cost-effectiveness analyses, which appears to be related, at least in part, to the substantial heterogeneity among the models used in the studies.…”

“…The analyses typically showed that the cost of a universal rotavirus vaccination program was partly offset by reductions in RVGE-related healthcare resource use and that the program was associated with quality-adjusted life-year (QALY) gains. However, the universal rotavirus vaccination program was deemed to be cost effective from the perspective of the healthcare payer only in some studies, [36,37,42,43] but not in others, [33][34][35][38][39][40]43] when applying commonly reported cost-effectiveness thresholds, such as h20 000-50 000, $US50 000, or d20 000-30 000 per QALY gained. [46][47][48][49] A consistent finding across studies that were conducted from both a healthcare payer and a societal (or 'limited societal') perspective was that incremental cost-effectiveness ratios (ICERs) were more favorable from a societal perspective, [33][34][35][36][37][38][39][40]43] as might be expected because additional costs associated with RVGE (e.g.…”